Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Company Overview - Legend Biotech Corporation is a global leader in cell therapy and the largest standalone cell therapy company with over 2,600 employees [3] - The company is pioneering CAR-T cell therapy, specifically with its product CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, developed in collaboration with Johnson & Johnson [3] - Legend Biotech aims to maximize patient access and therapeutic potential of CARVYKTI® while driving future innovation across its pipeline of cell therapy modalities [3] Upcoming Event - Legend Biotech will host a live webcast for investors on June 1, 2025, at 6:00 p.m. CT during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL [1] - The webcast will feature Ying Huang, Ph.D., CEO, and Mythili Koneru, M.D., Ph.D., CMO, along with expert clinicians discussing the latest updates from the CARTITUDE development program [2] - Interested parties can join the webcast through a provided weblink or visit Legend Biotech's website under Events and Presentations [2]